Current status of immunotherapy for gastrointestinal stromal tumor

Y. Tan, Jonathan Trent, Breelyn A Wilky, Darcy Kerr, Andrew Rosenberg

Research output: Contribution to journalReview article

14 Citations (Scopus)

Abstract

Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs.

Original languageEnglish (US)
Pages (from-to)130-133
Number of pages4
JournalCancer Gene Therapy
Volume24
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Gastrointestinal Stromal Tumors
Immunotherapy
Neoplasms
Natural Killer Cells
Macrophages
Galectins
T-Lymphocytes
T-Cell Antigen Receptor
Dendritic Cells
Anti-Idiotypic Antibodies
B-Lymphocytes
Clinical Trials
Antibodies

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Cancer Research

Cite this

Current status of immunotherapy for gastrointestinal stromal tumor. / Tan, Y.; Trent, Jonathan; Wilky, Breelyn A; Kerr, Darcy; Rosenberg, Andrew.

In: Cancer Gene Therapy, Vol. 24, No. 3, 01.03.2017, p. 130-133.

Research output: Contribution to journalReview article

@article{2397f29514274d0dbc325c68c034c56d,
title = "Current status of immunotherapy for gastrointestinal stromal tumor",
abstract = "Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs.",
author = "Y. Tan and Jonathan Trent and Wilky, {Breelyn A} and Darcy Kerr and Andrew Rosenberg",
year = "2017",
month = "3",
day = "1",
doi = "10.1038/cgt.2016.58",
language = "English (US)",
volume = "24",
pages = "130--133",
journal = "Cancer Gene Therapy",
issn = "0929-1903",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Current status of immunotherapy for gastrointestinal stromal tumor

AU - Tan, Y.

AU - Trent, Jonathan

AU - Wilky, Breelyn A

AU - Kerr, Darcy

AU - Rosenberg, Andrew

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs.

AB - Gastrointestinal stromal tumors (GIST) contain tumor-infiltrating immune cells and their presence provides an opportunity and rationale for developing effective forms of immunotherapy. The types of tumor-infiltrating inflammatory cells and relevant immune checkpoint inhibitors are the focus of active investigation. The most numerous tumor-infiltrating inflammatory cells are tumor-associated macrophages (TAMs) and CD3+ T cells. Studies have shown that patients with GISTs that harbor increased numbers of CD3+ T cells have better outcomes. However, the clinical behavior of GIST has not been shown to correlate with the number of TAMs. The biological significance of other less frequent tumor-infiltrating immune cells including tumor-infiltrating neurtrophils (TINs), natural killer cells (NKs), B cells, dendritic cells (DCs) remains unclear. The immune checkpoint inhibitors CTLA-4, PD1/PDL1 and TIM3/galectin-9 are molecules that can be targeted by synthesized antibodies. Clinical and pre-clinical trials using this approach against immune checkpoint inhibitors, anti-KIT antibody and the generation of chimeric antigen receptor (CAR) T-cells have shown promising results. The treatment of GIST with immunotherapy is complex and evolving; this article reviews its current status for patients with GISTs.

UR - http://www.scopus.com/inward/record.url?scp=85012188234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85012188234&partnerID=8YFLogxK

U2 - 10.1038/cgt.2016.58

DO - 10.1038/cgt.2016.58

M3 - Review article

VL - 24

SP - 130

EP - 133

JO - Cancer Gene Therapy

JF - Cancer Gene Therapy

SN - 0929-1903

IS - 3

ER -